Literature DB >> 23442608

Immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis vaccines in Iranian pre-school children, a randomized controlled trial.

Saeed Zarei1, Mahmood Jeddi-Tehrani, Mohammad Mehdi Akhondi, Hojjat Zeraati, Amir Ali Ferydonfar, Jalaledin Nasernia, Banafsheh Tavangar, Fazel Shokri.   

Abstract

The present study was undertaken to compare the immunogenicity and reactogenicity of two diphtheria-tetanus-whole cell pertussis (DTwP) vaccines administered to Iranian preschool children. In this randomized, double-blind and multicenter prospective study, 672 children aged 4-6 y were administered with either a local DTwP vaccine (DTwP-Local) (n = 337) or a commercial vaccine (DTwP-Pasteur) (n = 335). All subjects received DTwP vaccine at 4-6 y of age, following the national immunization schedule of Iran. Blood samples were collected before and 2-4 weeks after the vaccination. Immunogenicity of each vaccine was assessed by ELISA using commercial kits. Reactogenicity was assessed by the parents for seven days post-booster using diary cards. The geometric mean titers (GMTs) of the antibodies induced against diphtheria and tetanus by DTwP-Local were 7.7 and 9.4 IU/ml and those of DTwP-Pasteur were 8.2 and 8.6 IU/ml, respectively. There was no significant difference between the immunogenicity of the two vaccines against diphtheria and tetanus. The GMTs of antibodies produced against pertussis were 30.2 EU/ml for DTwP-Local and 47.9 EU/ml for DTwP-Pasteur vaccines (p<0.001). Pain and fever (axillary temperature>37.5°C) were the most frequent local and systemic reactions observed after the vaccination. All local and systemic reactions observed after vaccination were significantly higher in subjects immunized with DTwP-Local vaccine. Immunogenicity against diphtheria and tetanus was similar for the two vaccines, but immunogenicity of the local vaccine against pertussis was significantly less efficient than that of DTwP-Pasteur. This difference and the higher side effects of the DTwP-Local vaccine could be due to the bacterial strain or the preparation or formulation protocol of the local pertussis vaccine.

Entities:  

Keywords:  Diphtheria-tetanus-pertussis vaccine; enzyme-linked immunosorbent assay; immunogenicity; randomized controlled trial; reactogenicity; vaccination

Mesh:

Substances:

Year:  2013        PMID: 23442608      PMCID: PMC3901823          DOI: 10.4161/hv.24093

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

Review 1.  Understanding those who do not understand: a brief review of the anti-vaccine movement.

Authors:  G A Poland; R M Jacobson
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

Review 2.  Pertussis of adults and infants.

Authors:  C H Wirsing von König; S Halperin; M Riffelmann; N Guiso
Journal:  Lancet Infect Dis       Date:  2002-12       Impact factor: 25.071

3.  Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.

Authors:  Scott A Halperin; David Scheifele; Elaine Mills; Roland Guasparini; Garry Humphreys; Luis Barreto; Bruce Smith
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

4.  Immunogenicity of a combined diphtheria-tetanus-acellular pertussis vaccine in adults.

Authors:  Pierre Van Damme; Margaret Burgess
Journal:  Vaccine       Date:  2004-01-02       Impact factor: 3.641

5.  A model for developing countries of mass serological survey of children vaccinated against diphtheria and tetanus.

Authors:  F Nazari; H Mirchamsy; S Alé-Agha; M Mahinpour
Journal:  J Biol Stand       Date:  1976

6.  Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.

Authors:  M Blennow; M Granström; E Jäätmaa; P Olin
Journal:  Pediatrics       Date:  1988-09       Impact factor: 7.124

Review 7.  Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration.

Authors:  M Campins-Martí; H K Cheng; K Forsyth; N Guiso; S Halperin; L M Huang; J Mertsola; G Oselka; J Ward; C H Wirsing von König; F Zepp
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

8.  Distribution of pertussis antibodies among different age groups in Japan.

Authors:  Toshifumi Konda; Kazunari Kamachi; Masaaki Iwaki; Yasuko Matsunaga
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

9.  Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine.

Authors:  Pensri Kosuwon; Boonyarat Warachit; Yanee Hutagalung; Thitiporn Borkird; Pope Kosalaraksa; Hans L Bock; Yong Poovorawan
Journal:  Vaccine       Date:  2003-10-01       Impact factor: 3.641

10.  Acellular pertussis booster in adolescents induces Th1 and memory CD8+ T cell immune response.

Authors:  Nikolaus Rieber; Anna Graf; Dominik Hartl; Simon Urschel; Bernd H Belohradsky; Johannes Liese
Journal:  PLoS One       Date:  2011-03-08       Impact factor: 3.240

View more
  5 in total

Review 1.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

2.  Oral Diazepam in Febrile Seizures Following Acellular Pertussis Vaccination.

Authors:  Mohammadreza Ghazavi; Jafar Nasiri; Omid Yaghini; Rose Soltani
Journal:  Adv Biomed Res       Date:  2019-04-26

3.  Virulence Factors Variation Among Bordetella Pertussis Isolates in Iran.

Authors:  Vajiheh Sadat Nikbin; Nazanin Jannesar Ahmadi; Maryam Hosseinpour; Masoumeh Nakhost Lotfi; Fahimeh Shooraj; Fatemeh Sadeghpour; Fereshteh Shahcheraghi
Journal:  Int J Mol Cell Med       Date:  2015

4.  Genetic Profile Variation in Vaccine Strains and Clinical Isolates of Bordetella pertussis Recovered from Iranian Patients.

Authors:  Faezeh Haghighi; Fereshteh Shahcheraghi; Ebrahim Abbasi; Seyed Saeed Eshraghi; Hojjat Zeraati; Seyed Ali Javad Mousavi; Hossein Asgarian-Omran; Masoumeh Douraghi; Fazel Shokri
Journal:  Avicenna J Med Biotechnol       Date:  2014-07

5.  Genomic epidemiology of Iranian Bordetella pertussis: 50 years after the implementation of whole cell vaccine.

Authors:  Azadeh Safarchi; Sophie Octavia; Vajihe Sadat Nikbin; Masoumeh Nakhost Lotfi; Seyed Mohsen Zahraei; Chin Yen Tay; Binit Lamichhane; Fereshteh Shahcheraghi; Ruiting Lan
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.